Subtype
Prostate Carcinoma
CI-CAN-00006533Explore in graph →
431 active trials16 approved drugs20 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00006533Explore in graph →
Clinical trials
1,178 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (184)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06334432 | Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 466 | Nuvation Bio Inc.INDUSTRY | 1 | Jan 14, 2026 | clinicaltrials |
| NCT04647526 | Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment(SPLASH) | active not recruiting | Phase 3 | 455 | POINT Biopharma, a wholly owned subsidiary of Eli Lilly and CompanyINDUSTRY | 6 |
| Jan 13, 2026 |
| clinicaltrials |
| NCT04686682 | A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors | recruiting | Phase 1 / Phase 2 | 152 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 9, 2026 | clinicaltrials |
| NCT04777071 | An Investigational Scan (68Ga-PSMA-11 PET) for the Imaging of Prostate Cancer | active not recruiting | Phase 2 | 141 | University of WashingtonOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT04870515 | Diet and Physical Activity Intervention for the Prevention of ADT-Induced Metabolic Changes in Patients With Prostate Cancer, TRIPLE-A PILOT Study | completed | N/A | 20 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT01995058 | Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC | terminated | Phase 2 | 54 | ExelixisINDUSTRY | 1 | Jan 8, 2026 | clinicaltrials |
| NCT05570994 | 177Lu-HTK03170 in mCRPC With PSMA Positive Disease | enrolling by invitation | Phase 1 / Phase 2 | 50 | British Columbia Cancer AgencyOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT06866938 | Study of Re-treatment With [177Lu]Lu-PSMA in Men With Metastatic Castration Resistance Prostate Cancer(ReaLuP) | recruiting | Phase 2 | 58 | Hospices Civils de LyonOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT04763980 | Community-Based Health Coach for Access to Germline Genetic Testing Among African American Men With Prostate Cancer | recruiting | N/A | 72 | University of California, San FranciscoOTHER | 1 | Dec 31, 2025 | clinicaltrials |
| NCT06531499 | A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study(RADIODOSE) | recruiting | Phase 1 | 106 | Novartis PharmaceuticalsINDUSTRY | 6 | Dec 31, 2025 | clinicaltrials |
| NCT07310355 | 68Ga-PSMA-0057 and 177Lu-PSMA-0057 in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer | not yet recruiting | Phase 1 / Phase 2 | 49 | Chengdu StarRay Therapeutics Co., LtdINDUSTRY | 0 | Dec 30, 2025 | clinicaltrials |
| NCT05519878 | Light Therapy and Occupational Therapy Fatigue Management-Based Intervention for Patients With Genitourinary Cancers | recruiting | N/A | 224 | City of Hope Medical CenterOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT07302763 | Four-Timepoint Multi-tracer PET Imaging to Characterize Metastatic prOstate Cancer Heterogeneity(4TMPO) | recruiting | N/A | 45 | Frederic PouliotOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT06822491 | Early Magnetic Resonance Imaging Response of the Dominant Intraprostatic Lesion After Online Adaptive Stereotactic Body Radiotherapy for Localized Prostate Cancer and Correlation With Prostate Specific Antigen Response(PRODART) | active not recruiting | — | 28 | University of ZurichOTHER | 1 | Dec 23, 2025 | clinicaltrials |
| NCT06155084 | A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in mCRPC Patients | recruiting | Phase 1 / Phase 2 | 84 | Hinova Pharmaceuticals Inc.INDUSTRY | 1 | Dec 22, 2025 | clinicaltrials |
| NCT06229366 | [Ac-225]-PSMA-62 Trial in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate Cancer(ACCEL) | active not recruiting | Phase 1 | 142 | Eli Lilly and CompanyINDUSTRY | 1 | Dec 22, 2025 | clinicaltrials |
| NCT04446117 | Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC(CONTACT-02) | active not recruiting | Phase 3 | 575 | ExelixisINDUSTRY | 27 | Dec 18, 2025 | clinicaltrials |
| NCT05998278 | Personalized Optimization of Systematic Prostate Biopsy | recruiting | N/A | 330 | Fujian Medical University Union HospitalOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT06200259 | Reduction of Gastrointestinal Toxicity in Prostate Cancer by Proton Spot Placement | recruiting | N/A | 500 | Covenant Health Cancer CenterOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT02600156 | Focal Laser Ablation of Low to Intermediate Prostate Cancer Tumors | completed | N/A | 7 | Mayo ClinicOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT06347809 | DNA Methylation in Adenocarcinoma of the Prostate: Analysis of Validated Biomarkers in Urine | terminated | — | 24 | Mayo ClinicOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT06105918 | Radioligand Therapy After PSMA PET Guided External Beam Radiotherapy for Treating Post-Prostatectomy Patients With Biochemically Recurrent Prostate Cancer | active not recruiting | Phase 1 | 6 | Emory UniversityOTHER | 1 | Dec 9, 2025 | clinicaltrials |
| NCT03511196 | Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer | active not recruiting | Early Phase 1 | 17 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT05064111 | Utility of Adding MR Fusion to Standard US Guided Prostate Biopsy | suspended | — | 100 | University of ArizonaOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT04447703 | Technology-Enhanced Acceleration of Germline Evaluation for Therapy, TARGET Study | completed | N/A | 346 | Thomas Jefferson UniversityOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT04543903 | Neoadjuvant Interstitial Brachytherapy Using Diffusing Alpha Emitters Radiation Therapy in Men With Prostate Cancer | completed | N/A | 1 | Alpha Tau Medical LTD.INDUSTRY | 1 | Dec 2, 2025 | clinicaltrials |
| NCT06128525 | Prostate Resection After Microwave Ablation (PRAMA) | completed | N/A | 1 | University of Southern CaliforniaOTHER | 1 | Nov 28, 2025 | clinicaltrials |
| NCT07251829 | Neoadjuvant Embolization and Cytoreduction in Prostate Cancer | not yet recruiting | Phase 2 | 35 | Srinivas RamanOTHER | 0 | Nov 26, 2025 | clinicaltrials |
| NCT02023463 | Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer | active not recruiting | Phase 1 | 25 | Thomas Jefferson UniversityOTHER | 1 | Nov 25, 2025 | clinicaltrials |
| NCT06126731 | Combination Study of Antibiotics With Enzalutamide (PROMIZE) | recruiting | Phase 1 / Phase 2 | 39 | Institute of Cancer Research, United KingdomOTHER | 2 | Nov 24, 2025 | clinicaltrials |
| NCT07244393 | Lutetium (177Lu) DGUL Combined With Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer | not yet recruiting | Phase 1 | 30 | Cellbion Co., Ltd.INDUSTRY | 0 | Nov 24, 2025 | clinicaltrials |
| NCT07164794 | Memantine Hydrochloride in Prostate Cancer Patients | not yet recruiting | Phase 2 | 15 | Bin XuOTHER | 0 | Nov 19, 2025 | clinicaltrials |
| NCT05256381 | A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors | terminated | Phase 2 | 166 | SOTIO Biotech AGINDUSTRY | 9 | Nov 17, 2025 | clinicaltrials |
| NCT03582475 | Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate | active not recruiting | Phase 1 | 15 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Nov 12, 2025 | clinicaltrials |
| NCT05037500 | Decitabine/Cedazuridine and Enzalutamide for the Treatment of Metastatic Castrate Resistant Prostate Cancer | terminated | Phase 1 | 8 | Roswell Park Cancer InstituteOTHER | 1 | Nov 12, 2025 | clinicaltrials |
| NCT03541850 | Stereotactic Body Radiation Therapy in Treating Patients With Localized Prostate Cancer That Have Undergone Surgery | active not recruiting | Phase 2 | 92 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Nov 6, 2025 | clinicaltrials |
| NCT03734653 | Testosterone Therapy in Castration Resistant Prostate Cancer | completed | Early Phase 1 | 30 | University of Colorado, DenverOTHER | 1 | Nov 6, 2025 | clinicaltrials |
| NCT06062745 | Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT | recruiting | Phase 1 | 30 | Brigham and Women's HospitalOTHER | 1 | Nov 5, 2025 | clinicaltrials |
| NCT03860961 | Increasing the Dose of Survivorship Care Planning in Improving Care and Outcomes in Prostate Cancer Survivors Receiving Androgen Deprivation Therapy | completed | N/A | 550 | NRG OncologyOTHER | 1 | Nov 3, 2025 | clinicaltrials |
| NCT03480646 | ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 175 | Constellation PharmaceuticalsINDUSTRY | 1 | Oct 29, 2025 | clinicaltrials |
| NCT02203695 | Randomized Salvage Radiation Therapy Plus Enzalutamide Post Prostatectomy | completed | Phase 2 | 86 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Oct 28, 2025 | clinicaltrials |
| NCT05779943 | Comparison of 18F-rhPSMA-7.3 PET/CT With and Without Furosemide in Biochemical Recurrence of Prostate Cancer | active not recruiting | Phase 2 | 20 | Emory UniversityOTHER | 1 | Oct 27, 2025 | clinicaltrials |
| NCT05919329 | Evaluation of the Change in PSMA Expression in Prostate Cancer in Response to Hormonal Therapy | recruiting | Phase 4 | 80 | OHSU Knight Cancer InstituteOTHER | 1 | Oct 24, 2025 | clinicaltrials |
| NCT04910425 | PSMA-Targeted 18F-DCFPyL PET/MRI for the Detection of Prostate Cancer | withdrawn | Phase 2 | 0 | Northwestern UniversityOTHER | 1 | Oct 21, 2025 | clinicaltrials |
| NCT02141438 | Observational Study for the Evaluation of Long-term Safety of Radium-223 Used for the Treatment of Metastatic Castration Resistant Prostate Cancer(REASSURE) | completed | — | 1,472 | BayerINDUSTRY | 20 | Oct 16, 2025 | clinicaltrials |
| NCT03792841 | Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPC | terminated | Phase 1 | 212 | AmgenINDUSTRY | 10 | Oct 16, 2025 | clinicaltrials |
| NCT03580499 | Vitamin B6 in Reducing Hot Flashes in Participants With Prostate Cancer Undergoing Antiandrogen Therapy | completed | N/A | 43 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Oct 15, 2025 | clinicaltrials |
| NCT06141993 | ARCTIC: Liquid Biomarkers in the Prospective Androgen Receptor Signaling Inhibitors (ARSI) Resistance Clinical Trials(ARCTIC) | recruiting | — | 120 | Duke UniversityOTHER | 1 | Oct 15, 2025 | clinicaltrials |
| NCT03939689 | I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW).(ARROW) | completed | Phase 2 | 120 | Progenics Pharmaceuticals, Inc.INDUSTRY | 2 | Oct 14, 2025 | clinicaltrials |
| NCT07210502 | Side Effects of Low Dose Rate Brachytherapy and Ultra-hypofractionated Radiotherapy in Low to Intermediate Risk Prostate Cancer(LDR BURST) | not yet recruiting | N/A | 220 | Royal Surrey County Hospital NHS Foundation TrustOTHER | 1 | Oct 7, 2025 | clinicaltrials |
Data updated 24 days agoSource updated Jan 14, 2026source: clinicaltrials